Relevant of neutralizing antibody during SARS-CoV-2 infection and their therapeutic usage.

Gupta, Sneh Lata; Jaiswal, Rishi K

Gupta, Sneh Lata; Jaiswal, Rishi K.

Gupta SL; National Institute of Immunology, New Delhi, 110067, India.
Jaiswal RK; Department of Cancer Biology, Cardinal Bernardin Cancer Center, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, 60153, USA. rishijai24@gmail.com.

Mol Biol Rep ; 49(10): 10137-10140, 2022 10.

Article in English | MEDLINE | ID: covidwho-1942411

Subject(s)

Antibodies, Neutralizing; COVID-19; Antibodies, Neutralizing/therapeutic use; Antibodies, Viral/therapeutic use; Humans; SARS-CoV-2; Spike Glycoprotein, Coronavirus

Keywords

Delta variant; Neutralizing antibodies; Omicron variant; Receptor binding domain (RBD); SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 Limits: Humans Language: English Journal: Mol Biol Rep Year: 2022 Document Type: Article Affiliation country: S11033-022-07493-z

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google